Reinforcement of Positive Electrode-Electrolyte Interface without Using Electrolyte Additives Through Thermoelectrochemical Oxidation of LiPF6 for Lithium Secondary Batteries.

Owing to the limited electrochemical stability window of carbonate electrolytes, the initial formation of a solid electrolyte interphase and surface film on the negative and positive electrode surfaces by the decomposition of the electrolyte component is inevitable for the operation of lithium secondary batteries. The deposited film on the surface of the active material is vital for reducing further electrochemical side reactions at the surface; hence, the manipulation of this formation process is necessary for the appropriate operation of the assembled battery system. In this study, the thermal decomposition of LiPF6 salt is used as a surface passivation agent, which is autocatalytically formed during high-temperature storage. The thermally formed difluorophosphoric acid is subsequently oxidized on the partially charged high-Ni positive electrode surface, which improves the cycleability of lithium metal cells via phosphorus- and fluorine-based surface film formation. Moreover, the improvement in the high-temperature cycleability is demonstrated by controlling the formation process in the lithium-ion pouch cell with a short period of high-temperature storage before battery usage.

Interface Engineering with Nonsacrificial Perfluorinated-Anion Additives for Boosting the Kinetics of Lithium-Ion Batteries.

Though lithium-ion batteries (LIBs) have seen a meteoric rise in worldwide deployment over the last decade, they should be further advanced in constant demand of higher rate capability and wider temperature adaptability. A solid electrolyte interphase (SEI) is the essential part of LIBs, determining the charge-discharge performance and degradation behavior. Herein, improvement of the SEI properties is achieved by regulating the electrochemical double layer structure with a nonsacrificial electrolyte additive, that is, lithium nonafluoro-1-butanesulfonate. The anion adsorption of the additive affects the decomposition behavior of other additive and solvent species, and the generated SEI at the graphite electrode becomes thinner and more uniform, leading to decreased impedance and finally resulting in improved energy efficiency, power capability, and fast charging performance of the graphite/NCM811 cell. Furthermore, the low-temperature cycleability at -20 °C is considerably enhanced with no dendritic Li metal deposition at the negative electrode surface. A mechanistic study on the interfacial phenomena and the effect is carried out by using various theoretical and experimental methods, such as density functional theory calculations, electrochemical quartz crystal microbalance, and transmission electron microscopy. Consequently, the approach of SEI modification with the nonsacrificial electrolyte additive can be one of the effective ways to advance LIB technology in future.

Combined venetoclax and alvocidib in acute myeloid leukemia.

More effective treatment options for elderly acute myeloid leukemia (AML) patients are needed as only 25-50% of patients respond to standard-of-care therapies, response duration is typically short, and disease progression is inevitable even with some novel therapies and ongoing clinical trials. Anti-apoptotic BCL-2 family inhibitors, such as venetoclax, are promising therapies for AML. Nonetheless, resistance is emerging. We demonstrate that venetoclax combined with cyclin-dependent kinase (CDK) inhibitor alvocidib is potently synergistic in venetoclax-sensitive and -resistant AML models in vitro, ex vivo and in vivo. Alvocidib decreased MCL-1, and/or increased pro-apoptotic proteins such as BIM or NOXA, often synergistically with venetoclax. Over-expression of BCL-XL diminished synergy, while knock-down of BIM almost entirely abrogated synergy, demonstrating that the synergistic interaction between alvocidib and venetoclax is primarily dependent on intrinsic apoptosis. CDK9 inhibition predominantly mediated venetoclax sensitization, while CDK4/6 inhibition with palbociclib did not potentiate venetoclax activity. Combined, venetoclax and alvocidib modulate the balance of BCL-2 family proteins through complementary, yet variable mechanisms favoring apoptosis, highlighting this combination as a promising therapy for AML or high-risk MDS with the capacity to overcome intrinsic apoptosis mechanisms of resistance. These results support clinical testing of combined venetoclax and alvocidib for the treatment of AML and advanced MDS.